Novartis announces positive results for Siponimod
Posted: Thu Aug 25, 2016 1:07 am
Novartis AG has said that a late-stage study has shown the oral, once-daily BAF312 drug, or Siponimod, reduced the risk of disability progression in a severe form of multiple sclerosis...Read more - http://www.ms-uk.org/novartis-announces ... mod-250816